Study Population The population eligible for inclusion was adults (aged 18.0 years) with both CKD (stage 24 or stage unspecified) and type 2 diabetes who initiated either an SGLT2i or GLP-1 RA in the later period (9 July 2021 [i.e., the FDA approval date of finerenone] to 30 September 2023) with at least 12 months of continuous enrollment before medication initiation (ESM Fig
GarciaPelaez, J., BarbosaMatos, R., Gullo, I., Carneiro, F
To ensure peptide stability, sterility, and safety, experts highly recommend reconstituting melanotan and other research peptides with high-quality bacteriostatic water sourced from a trusted vendor
Each will likely follow the same 30/27 BMI framework for weight management approval, though the actual prescribing landscape will depend on individual approval timelines and the specific populations studied in phase 3 trials
This reduces strain on healthcare systems and expands global access